Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
4
×
national blog main
boston blog main
biotech
boston
boston top stories
cancer
indiana blog main
indiana top stories
new york blog main
new york top stories
type 1 diabetes
abeona therapeutics
accent therapeutics
achilles therapeutics
akouos
aldehyde
alder biopharmaceuticals
aldeyra therapeutics
alexion pharmaceuticals
allergic conjunctivitis
alnylam pharmaceuticals
alopecia areata
amarin
amgen
andrew berens
aridis pharmaceuticals
aristea therapeutics
autoimmune diseases
avapritinib
axitinib
bellus health
biotech ipos
blueprint medicines
boehringer ingelheim
bolt biotherapeutics
boulder/denver blog main
boulder/denver top stories
bridgebio
What
drug
type
4
×
fda
approval
filing
medicine
new
patients
advantages
aldeyra
announced
bar
bid
bio
blueprint
boehringer
brings
cancer
chasing
closer
data
deadly
deciphera
diabetes
disclosed
eli
expand
expect
eye
fallen
fighting
forms
gamble
gi
inflammation
ingelheim
lilly
market
marketed
medco’s
Language
unset
Current search:
type
×
" life sciences "
×
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug